Treatment of immune-mediated anemia (IMHA) with prednisolone alone versus atopica in cats
Immune-mediated hemolytic anemia is a disease in cats where their own immune system can attack their red blood cells resulting in anemia. The purpose of this study is to look at two different treatment protocols for the treatment of his disease in cats.
The study covers care including blood work and diagnostic visits and treatment (medications) for one year of enrollment.
condition(s)
immune mediated hemolytic anemia
eligibility information
- Cats eligible for inclusion in the trial can not have any underlying causes of IMHA such as infectious diseases (e.g FeLV) or neoplasia (cancer).
- Cats diagnosed with IMHA thought to be due to the immune system and not secondary to other causes are eligible for inclusion.
- Cats cannot be receiving immunosuppressive therapy such as steroids for over 48 hours or other types of medications (Atopica, chlorambucil, etc).
Enrollment Deadline
Enrollment ends January 1, 2028
contact information
If you have any questions about eligibility for this study, please contact Dr. Sarah Shropshire at [email protected].
